Additionally, JDQ443 will be evaluated as a single-agent as a first-line treatment for patients with advanced NSCLC whose tumors harbor a KRAS G12C mutation and PD-L1 expression <1% regardless of STK11 mutation status, or a PD-L1 expression ≥1% and STK11 co-mutation. This evidence concerns the gene CD274 and non-small cell lung carcinoma.